logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhageClinical Trial Updates

23 Apr 2026

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

George Medicines announced the publication of results from its global, investigator-initiated TRIDENT trial in the New England Journal of Medicine. The trial...

Merck’s fast-ascending kidney cancer drug hits a setbackClinical Trial Updates

22 Apr 2026

Merck’s fast-ascending kidney cancer drug hits a setback

Merck & Co.'s Welireg, in a three-drug combination with Keytruda and Lenvima, failed to meet its dual main objectives in a Phase 3 trial for newly diagnosed...

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMSClinical Trial Updates

22 Apr 2026

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Roche announced positive Phase III FENhance 1 and 2 study results for fenebrutinib in relapsing multiple sclerosis (RMS). The investigational non-covalent BTK...

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGADClinical Trial Updates

22 Apr 2026

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

Roche announced positive Phase III METEOROID study results for ENSPRYNG (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein...

Gilead, Arcus tumble again in TIGIT, triggering 2 trial cullsClinical Trial Updates

22 Apr 2026

Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls

Gilead Sciences and Arcus Biosciences are discontinuing their Phase 3 STAR-121 study of the investigational TIGIT drug domvanalimab in combination with a PD-1...

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 TrialClinical Trial Updates

22 Apr 2026

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

Regeneron Pharmaceuticals announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized...

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from Highest Dose Cohort in RESOLVE TrialClinical Trial Updates

22 Apr 2026

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from Highest Dose Cohort in RESOLVE Trial

Eupraxia Pharmaceuticals announced positive 36-week tissue health and symptom data from the highest dose cohort (Cohort 9, n=3) of its ongoing Phase 1b/2a...

Novo Nordisk's Etavopivat Meets Co-Primary Endpoints in Phase 3 HIBISCUS Trial for Sickle Cell DiseaseClinical Trial Updates

22 Apr 2026

Novo Nordisk's Etavopivat Meets Co-Primary Endpoints in Phase 3 HIBISCUS Trial for Sickle Cell Disease

Novo Nordisk announced positive topline results from its pivotal Phase 3 HIBISCUS trial of once-daily oral etavopivat in adults and adolescents with sickle...

Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’Clinical Trial Updates

22 Apr 2026

Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’

Merck and Sino Biopharmaceutical's investigational anti-PD-1/VEGF bispecific antibody, MK-2010, showed competitive early-stage results in a Phase 1/2 study for...

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026Clinical Trial Updates

22 Apr 2026

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Cancer, Ltd. announced updated follow-up data from its Phase 1 UNO trial (NCT05351502) at the American Association for Cancer Research (AACR) Annual...

Nektar surges again as alopecia drug shows new promise in extension studyClinical Trial Updates

22 Apr 2026

Nektar surges again as alopecia drug shows new promise in extension study

Nektar Therapeutics announced that its experimental autoimmune drug, rezpegaldesleukin, demonstrated a deepening treatment response in an extension study for...

Agenus cancer cocktail records 0% response rate, missing midstage goalClinical Trial Updates

22 Apr 2026

Agenus cancer cocktail records 0% response rate, missing midstage goal

Agenus and its spinout MiNK Therapeutics reported that their investigational cocktail, comprising botensilimab, balstilimab, and agenT-797, combined with...

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025Clinical Trial Updates

03 Nov 2025

Amgen's Repatha Phase 3 VESALIUS-CV Trial Data to be Presented at AHA 2025

Amgen announced that new data from its cardiovascular portfolio, including results from the Phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab)...

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc AnalysisClinical Trial Updates

03 Nov 2025

GeneSight Test Shows Faster Remission and Response in Depression Treatment: Post-Hoc Analysis

Myriad Genetics announced a post-hoc analysis of the PRIME study, revealing that patients with Major Depressive Disorder (MDD) treated based on GeneSi...

Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus ErythematosusClinical Trial Updates

03 Nov 2025

Genentech's Gazyva Shows Positive Phase III Data with Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

Genentech announced positive results from the Phase III ALLEGORY study of Gazyva in adults with systemic lupus erythematosus (SLE) on standard therapy...

Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader ProgramsClinical Trial Updates

31 Oct 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, CBP, and EP300 Degrader Programs

Foghorn Therapeutics announced updates on its Selective ARID1B, CBP, and EP300 degrader programs. The Selective ARID1B degrader selectively binds and ...

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in VitiligoClinical Trial Updates

30 Oct 2025

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult and adolescent patients with n...

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid ArthritisClinical Trial Updates

30 Oct 2025

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

AnaptysBio announced positive late-breaking data from its Phase 2b trial of rosnilimab in rheumatoid arthritis (RA). The study demonstrated deepening ...

Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for ObesityClinical Trial Updates

30 Oct 2025

Wave Life Sciences Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity

Wave Life Sciences announced positive Activin E target engagement data from the INLIGHT clinical trial of WVE-007, a GalNAc-siRNA, for obesity. The tr...

Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia GravisClinical Trial Updates

29 Oct 2025

Kyverna Therapeutics Announces Positive Phase 2 Interim Data for KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics announced positive interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis (gMG). The data showed ...

TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple SclerosisClinical Trial Updates

29 Oct 2025

TG Therapeutics Completes Enrollment in Phase 3 ENHANCE Trial of Simplified Dosing for BRIUMVI in Multiple Sclerosis

TG Therapeutics announced the completion of enrollment in the Phase 3 ENHANCE trial, which is evaluating a simplified dosing schedule for BRIUMVI (ubl...

Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025Clinical Trial Updates

27 Oct 2025

Cullinan Therapeutics Presents Preclinical Data for CLN-978 Supporting Clinical Development in Autoimmune Diseases at ACR Convergence 2025

Cullinan Therapeutics presented preclinical data for CLN-978, a CD19xCD3 bispecific T cell engager, at the American College of Rheumatology (ACR) Conv...

Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF TrialClinical Trial Updates

27 Oct 2025

Daewoong Pharmaceutical's Bersiporocin Receives Positive IDMC Safety Review in Phase 2 IPF Trial

Daewoong Pharmaceutical announced that Bersiporocin (DWN12088), its first-in-class drug candidate for idiopathic pulmonary fibrosis (IPF), received a ...

Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 TrialClinical Trial Updates

27 Oct 2025

Innovent's Mazdutide Demonstrates Superior Glycemic Control and Weight Loss Compared to Semaglutide in Phase 3 DREAMS-3 Trial

Innovent Biologics announces positive results from its Phase 3 DREAMS-3 clinical trial of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (G...

Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis PatientsClinical Trial Updates

27 Oct 2025

Lilly's Omvoh (mirikizumab-mrkz) Shows Improvement in Bowel Urgency for Ulcerative Colitis Patients

Eli Lilly and Company announced positive data from the Phase 3b LUCENT-URGE study, demonstrating that Omvoh (mirikizumab-mrkz) significantly improved ...

Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic FibrosisClinical Trial Updates

27 Oct 2025

Sionna Therapeutics Announces Phase 1 Data for SION-719 and SION-451 and Preclinical Data on NBD1 Stabilizers in Cystic Fibrosis

Sionna Therapeutics announced the presentation of Phase 1 clinical trial data for SION-719 and SION-451, first-in-class NBD1 stabilizers, at the 2025 ...

Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell CarcinomaClinical Trial Updates

27 Oct 2025

Xencor Presents Phase 1 Data for XmAb819 in Clear Cell Renal Cell Carcinoma

Xencor announced initial results from the Phase 1 dose-escalation study of XmAb819, a first-in-class ENPP3 x CD3 bispecific T-cell engager, in patient...

Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia GravisClinical Trial Updates

23 Oct 2025

Kyverna Therapeutics Announces Conference Call on Interim Phase 2 Data of KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics will host a conference call to discuss interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 in generalized myas...

Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy EndpointClinical Trial Updates

23 Oct 2025

Moderna's Phase 3 CMV Vaccine Trial Fails to Meet Primary Efficacy Endpoint

Moderna announced that its Phase 3 trial evaluating mRNA-1647, an investigational cytomegalovirus (CMV) vaccine, did not meet its primary efficacy end...

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature MedicineClinical Trial Updates

22 Oct 2025

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine

AskBio, a subsidiary of Bayer AG, announced the publication of 12-month data from its Phase 1 trial of AB-1002 gene therapy for congestive heart failu...

OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma SubgroupsClinical Trial Updates

22 Oct 2025

OS Therapies Announces Positive Survival Data for OST-HER2 in Metastatic Osteosarcoma Subgroups

OS Therapies Inc. announced additional overall and event free survival data from its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected,...

Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk PregnancyClinical Trial Updates

22 Oct 2025

Rozanolixizumab Prevents Congenital Heart Block Recurrence in High-Risk Pregnancy

NYU Langone Health researchers found that rozanolixizumab, a neonatal Fc receptor (FcRn) inhibitor, can prevent congenital heart block in newborns of ...

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal MelanomaClinical Trial Updates

21 Oct 2025

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Neoadjuvant Primary Uveal Melanoma

IDEAYA Biosciences announced positive Phase 2 clinical data for darovasertib in the neoadjuvant setting of primary uveal melanoma (UM). The OptimUM-09...

Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic FibrosisClinical Trial Updates

21 Oct 2025

Sionna Therapeutics Initiates Phase 2a Trial of SION-719 for Cystic Fibrosis

Sionna Therapeutics has initiated the PreciSION CF Phase 2a trial to evaluate SION-719, a novel NBD1 stabilizer, in cystic fibrosis (CF) patients. The...

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine TumorsClinical Trial Updates

20 Oct 2025

AlphaMedix Phase 2 Data Shows Potential in Gastroenteropancreatic Neuroendocrine Tumors

AlphaMedix phase 2 study (ALPHAMEDIX-02) evaluating AlphaMedix (212Pb-DOTAMTATE) in patients with advanced gastroenteropancreatic neuroendocrine tumor...

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025Clinical Trial Updates

20 Oct 2025

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025

Apnimed announced additional data from its Phase 3 SynAIRgy and LunAIRo trials evaluating AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg) for obstructiv...

CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025Clinical Trial Updates

20 Oct 2025

CatalYm Presents Positive Long-Term Phase 1/2a Data for Visugromab in CPI-Refractory Tumors at ESMO 2025

CatalYm announced updated long-term data from its GDFATHER-1/2a trial at ESMO Congress 2025, showcasing the potential of visugromab to reverse resista...

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025Clinical Trial Updates

20 Oct 2025

Disc Medicine to Present Phase 1b Data of DISC-0974 in CKD Patients with Anemia at ASN Kidney Week 2025

Disc Medicine will present data from its Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anem...

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal CancerClinical Trial Updates

20 Oct 2025

Exelixis Announces Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combination in Metastatic Colorectal Cancer

Exelixis announced detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with atezolizumab versus regorafenib in...

Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025Clinical Trial Updates

20 Oct 2025

Olema Oncology Announces Positive Phase 1b/2 Data of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Olema Oncology announced updated data from the Phase 1b/2 study of palazestrant in combination with ribociclib in patients with ER+/HER2- advanced or ...

← PrevPage 3 of 10Next →